文献速递妇科

患者来源类器官作为妇科肿瘤临床前模型的高效利用

Efficient use of patient-derived organoids as a preclinical model for gynecologic tumors.
PubMed 文献 · Gynecol Oncol · 2019-05-14

该研究对21例妇科肿瘤进行3D培养,改良基质胶双层类器官培养方案以克服妇科肿瘤抗消化特性,将成功率从45%提高到90%,成功建立14例患者来源类器官,其保留原肿瘤的组织学特征、突变谱和瘤内异质性,并可用于体外紫杉醇和顺铂药敏检测。

要点

  • 改良基质胶双层类器官培养方案使妇科肿瘤类器官培养成功率从45%提高到90%。
  • 成功建立14例患者来源类器官,保留原肿瘤组织学特征、突变谱和瘤内异质性。
  • 部分扩增类器官可在免疫缺陷小鼠中形成异种移植瘤,体外紫杉醇和顺铂药敏检测可行。

核心结论

  • 患者来源类器官与原妇科肿瘤高度相似,有望作为临床前研究的资源。

研究设计与样本

  • 对21例妇科肿瘤进行3D培养,采用本研究的原始及改良基质胶双层类器官培养方案。
  • 通过组织病理学检查和靶向基因组测序评估扩增类器官是否保留原肿瘤特征。

主要发现

  • 改良方案克服妇科肿瘤抗消化特性,将类器官培养成功率从45%提高到90%。
  • 成功建立14例患者来源类器官,其富集癌细胞并保留原肿瘤的组织学特征、突变谱和瘤内异质性。
  • 部分扩增类器官可在免疫缺陷小鼠中形成异种移植瘤。
  • 利用类器官来源的球状体进行紫杉醇和顺铂体外药敏检测可行。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The relevance of patient-derived cancer cells has been recently increasing, particularly in terms of drug discovery and precision medicine. Whereas Matrigel-based organoid culture is a promising technique that enables infinite proliferation of cells from many types of organs in a physiological condition, its validity in gynecologic tumors remains to be established. To address this issue, we aimed at developing an efficient method for organoid culture of both ovarian and endometrial tumors. METHODS: We conducted 3D culture of 21 gynecologic tumors following our original and modified protocol for Matrigel bilayer organoid culture. We investigated whether propagated organoids retained various features of the original tumors by histopathological examination and targeted genome sequencing. RESULTS: We customized the protocol we previously optimized for murine normal and cancer tissues, so as to circumvent the digestion-resistant nature inherent to gynecologic tumors. Indeed, this modified protocol improved the success rate from 45 to 90%, for robust propagation of organoids from tumors with various stages and subtypes. Finally, 14 patient-derived organoids were established. The recovered organoids were enriched for cancer cells that retained many aspects of the original tumors, including histological features, mutation profiles, and intra-tumoral heterogeneity. A subset of the expanded organoids could develop xenografts in immunodeficient mice, potentially paving the way to drug screening in vivo. Drug response assay in vitro for paclitaxel and cisplatin was feasible using organoid-derived spheroids. CONCLUSIONS: We showed that patient-derived organoids closely resembled the original gynecologic tumors, and thereby would serve as a promising resource for preclinical studies.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Maru Y, Tanaka N, Itami M, et al. Efficient use of patient-derived organoids as a preclinical model for gynecologic tumors. Gynecol Oncol. 2019. PMID: 31101504. doi:10.1016/j.ygyno.2019.05.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。